Everest Medicines, Pfizer Receive FDA Clearance for Ulcerative Colitis Treatment
Etrasimod indicated for adult patients with moderate-to-severe diagnosis.
Everest Medicines revealed that Pfizer, its licensing partner, has received FDA approval for Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). Currently, Everest is in the process of conducting Phase III clinical trials of the medication in Asia with hopes of filing a new drug application.
"We congratulate our partner for achieving this significant milestone for UC patients who are in urgent need of new and effective treatment options and prefer the convenience of a once-daily pill. Etrasimod is a proven advanced treatment with a favorable safety profile." said Rogers Yongqing Luo, CEO, Everest Medicines, in a company press release. "Everest will advance our late-stage study as quickly as possible toward registration in China and other Asian markets as the incidence of ulcerative colitis has been rapidly increasing in the region in recent years."
Reference: Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis. PR Newswire. October 15, 2023. Accessed October 16, 2023. https://www.prnewswire.com/news-releases/everest-medicines-licensing-partner-pfizer-announces-us-fda-approves-etrasimod-for-adults-with-moderately-to-severely-active-ulcerative-colitis-301956907.html
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
